Phase I, Single-centre, Randomised, Placebo-controlled, Double-blinded Study, With Single Ascending Dose and Multiple Dose at Maximum Tolerated Dose, Evaluating the Safety, Tolerability and Pharmacokinetics of ALX-0171, Administered by Pulmonary Inhalation, in Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2012
At a glance
- Drugs ALX 0171 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- 01 Sep 2012 Status changed from active, no longer recruiting to completed.
- 08 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 Dec 2011 Status changed from not yet recruiting to recruiting, according to an Ablynx media release.